immunotherapy

TriSalus Life Sciences Announces Key Appointments to Board of Directors

HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic CancersDENVER--(BUSINESS WIRE)--TriSalus…

10 months ago

Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members

Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy…

10 months ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors…

10 months ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors…

10 months ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors…

10 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity…

10 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity…

10 months ago

Immutep Quarterly Activities Report Q2 FY25

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung…

10 months ago

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

10 months ago

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with…

10 months ago